This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of PICOPREP in Patients Needed to Clean the Bowel Prior to X-ray Examination, Endoscopy or Surgery.

This study has been completed.
Information provided by (Responsible Party):
Ferring Pharmaceuticals Identifier:
First received: February 8, 2011
Last updated: February 8, 2012
Last verified: February 2012
The study serves as a confirmation of safety, tolerance and efficacy of PICOPREP in clinical practice.

Condition Intervention
Bowel Cleanliness Drug: sodium picosulphate

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Compliance and Efficacy in the Use of PICOPREP for Bowel Cleansing

Resource links provided by NLM:

Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Documentation of use PICOPREP in everyday practice [ Time Frame: Day 0 - 2 ]

Secondary Outcome Measures:
  • Participant satisfaction and compliance after bowel cleansing [ Time Frame: Days 0-2 ]
  • Participants with adverse events reported by frequency and severity [ Time Frame: Days 1-2 ]

Enrollment: 252
Study Start Date: December 2010
Study Completion Date: February 2012
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
PICOPREP® Drug: sodium picosulphate
Sodium picosulphate (PICOPREP®) taken by participant prior to X-ray examination, endoscopy or surgery.
Other Name: PICOPREP®


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients about to undergo X-ray examination, endoscopy or surgery.

Inclusion Criteria:

  • Patients receiving PICOPREP® for bowel evacuation prior to endoscopy or surgery

Exclusion Criteria:

  • Patients in which prescription of PICOPREP® is contraindicated
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01292109

Czech Republic
University Hospital
Ostrava - Poruba, Czech Republic
University Hospital
Pilsen, Czech Republic
Iscare - Prague 7
Prague 7, Czech Republic
Sponsors and Collaborators
Ferring Pharmaceuticals
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Ferring Pharmaceuticals Identifier: NCT01292109     History of Changes
Other Study ID Numbers: FE999169 CS03
Study First Received: February 8, 2011
Last Updated: February 8, 2012

Keywords provided by Ferring Pharmaceuticals:
preparation for surgery

Additional relevant MeSH terms:
Picosulfate sodium
Gastrointestinal Agents processed this record on August 22, 2017